Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases

Study of U.S. veterans with type 2 diabetes, on SGLT2is (n=8544), GLP-1 (n=23,711), DPP-4 (n=39,399), or sulfonylureas (n=134,904) who were followed for up to 3 years, found treatment with SGLT2is or GLP-1 vs. DPP-4 or sulfonylureas linked to lower risk of adverse kidney outcomes

Diabetes Care